May 2, 2019
Awareness of Fatty Liver Disease Remains Low Among Most At-Risk Patients
Results of a new survey show that even among patients at highest risk for nonalcoholic steatohepatitis (NASH), awareness of the…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: nonalcoholic fatty liver disease (NAFLD)
February 22, 2018
BASF introduces Hepaxa in the U.S. for non-alcoholic fatty liver disease patients
BASF Corporation is introducing Hepaxa, a product that can help tens of millions of patients manage Non-Alcoholic Fatty Liver Disease…
January 31, 2018
Gemphire Therapeutics seeks evidence for gemcabene as treatment for pediatric nonalcoholic fatty liver disease
Gemphire Therapeutics, a US based clinical-stage biopharmaceutical company focused on therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), has…
April 20, 2017
Allergan and Target PharmaSolutions join to fight certain type of liver disease
Allergan will collaborate with Target PharmaSolutions on its five-year longitudinal observational study that looks at patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).